CN117479930A - 用于治疗癫痫发作病症的药物组合物和方法 - Google Patents

用于治疗癫痫发作病症的药物组合物和方法 Download PDF

Info

Publication number
CN117479930A
CN117479930A CN202280041014.0A CN202280041014A CN117479930A CN 117479930 A CN117479930 A CN 117479930A CN 202280041014 A CN202280041014 A CN 202280041014A CN 117479930 A CN117479930 A CN 117479930A
Authority
CN
China
Prior art keywords
once
days
seizures
transdermal
epilepsy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280041014.0A
Other languages
English (en)
Chinese (zh)
Inventor
福提奥斯·M·普拉科吉亚尼斯
特曼娜·拉瑟
尼萨格·莫迪
马里纳·博罗文斯卡娅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spear Therapy Co ltd
Original Assignee
Spear Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/225,654 external-priority patent/US12016829B2/en
Application filed by Spear Therapy Co ltd filed Critical Spear Therapy Co ltd
Publication of CN117479930A publication Critical patent/CN117479930A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280041014.0A 2021-04-08 2022-04-07 用于治疗癫痫发作病症的药物组合物和方法 Pending CN117479930A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/225,654 2021-04-08
US17/225,654 US12016829B2 (en) 2019-10-11 2021-04-08 Pharmaceutical composition and method for treating seizure disorders
PCT/IB2022/053271 WO2022215030A1 (en) 2021-04-08 2022-04-07 Pharmaceutical composition and method for treating seizure disorders

Publications (1)

Publication Number Publication Date
CN117479930A true CN117479930A (zh) 2024-01-30

Family

ID=83546168

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280041014.0A Pending CN117479930A (zh) 2021-04-08 2022-04-07 用于治疗癫痫发作病症的药物组合物和方法

Country Status (7)

Country Link
EP (1) EP4319730A4 (https=)
JP (1) JP2024514843A (https=)
CN (1) CN117479930A (https=)
AU (1) AU2022255944A1 (https=)
CA (1) CA3213953A1 (https=)
MX (1) MX2023011821A (https=)
WO (1) WO2022215030A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4041209A4 (en) 2019-10-11 2024-01-24 Pike Therapeutics, Inc. TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS
AU2022257344A1 (en) * 2021-04-12 2023-10-26 Pike Therapeutics Inc. Transdermal delivery of cannabidiol

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2760460C (en) * 2009-04-28 2019-04-02 Alltranz Inc. Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same
EP2424568A1 (en) * 2009-04-29 2012-03-07 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
PT2473475T (pt) * 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
HK1244715A1 (zh) * 2015-03-02 2018-08-17 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
US9962340B2 (en) * 2015-06-09 2018-05-08 Life Tech Global, Llc Device and method for the transdermal delivery of cannabidiol
US10272125B2 (en) * 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
CN109498606A (zh) * 2017-09-15 2019-03-22 汉义生物科技（北京）有限公司 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用
US20190083388A1 (en) * 2017-09-19 2019-03-21 Zynerba Pharmaceuticals, Inc. Synthentic transdermal cannabidiol for the treatment of focal epilepsy in adults
US10821084B2 (en) * 2018-01-31 2020-11-03 Remy Biosciences, Inc. Dihydromyricetin compositions
BR112022004175A2 (pt) * 2019-09-17 2022-05-31 Zynerba Pharmaceuticals Inc Tratamento de encefalopatia de syngap1
EP4041209A4 (en) * 2019-10-11 2024-01-24 Pike Therapeutics, Inc. TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS
CA3155181A1 (en) * 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
KR20230113622A (ko) * 2020-12-03 2023-07-31 지네르바 파마슈티컬스, 인코포레이티드 난치성 발작의 치료를 위한 칸나비디올

Also Published As

Publication number Publication date
JP2024514843A (ja) 2024-04-03
AU2022255944A1 (en) 2023-10-12
EP4319730A1 (en) 2024-02-14
EP4319730A4 (en) 2025-03-12
WO2022215030A1 (en) 2022-10-13
MX2023011821A (es) 2023-10-13
CA3213953A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
JP7670700B2 (ja) 発作性障害の治療用のカンナビジオール（ｃｂｄ）を含む経皮医薬組成物
US20250248948A1 (en) Transdermal and/or Topical, Pharmaceutical Formulations Comprising Cannabidiol and/or Tetrahydrocannabinol for the Treatment of Chronic Pain
US20260076921A1 (en) Transdermal Pharmaceutical Formulations for the Treatment of Multiple Sclerosis
CN115884761A (zh) 大麻素的透皮药物制剂
US20240261235A1 (en) Pharmaceutical Composition And Method For Treating Seizure Disorders
JP2022550569A (ja) ドロナビノールの経皮送達
US12409131B2 (en) Transdermal delivery of dronabinol
CN117479930A (zh) 用于治疗癫痫发作病症的药物组合物和方法
CN117545478A (zh) 用于治疗慢性疼痛的透皮药物制剂
US20250049821A1 (en) Pharmaceutical Composition and Method for Treating Seizure Disorders
JP3841628B2 (ja) 経皮吸収剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination